What evidence is available regarding emerging and investigational treatment options for metastatic brain tumors? TARGET POPULATION: Adult patients with brain metastases.
QUESTION:
What evidence is available regarding emerging and investigational treatment options for metastatic brain tumors? TARGET POPULATION: Adult patients with brain metastases.
RECOMMENDATIONS: HIGH-INTENSITY FOCUSED ULTRASOUND
There is insufficient evidence to make a recommendation regarding the use of highintensity focused ultrasound (HIFU) for the treatment of patients with brain metastases.
LASER INTERSTITIAL THERMAL THERAPY
There is insufficient evidence to make a recommendation regarding the routine use of laser interstitial thermal therapy (LITT), aside from use as part of approved clinical trials.
RADIATION SENSITIZERS Level 1:
The use of temozolomide as a radiation sensitizer is not recommended in the setting of whole-brain radiotherapy (WBRT) for patients with breast cancer brain metastases. Level 1: The use of chloroquine as radiation sensitizer is not recommended in the setting of WBRT for patients with brain metastases. There is insufficient evidence to make a recommendation regarding the routine use of radiation sensitizers, such as motexafin-gadolinium, sodium nitrite, temozolomide, or chloroquine, in other clinical settings for patients with brain metastases.
INTERSTITIAL MODALITIES
There is insufficient evidence to make a recommendation regarding the routine use of existing local therapies, such as interstitial chemotherapy, brachytherapy, or other local modalities, aside from their use in approved clinical trials.
IMMUNE MODULATORS
There is insufficient evidence to make a recommendation regarding the use of immune therapy for brain metastases.
MOLECULAR TARGETED AGENTS
Level 1: The use of afatinib is not recommended in patients with brain metastasis due to breast cancer. There is insufficient evidence to make recommendations regarding: 1. the use of epidermal growth factor receptor inhibitors erlotinib and gefitinib in patients with brain metastasis due to nonsmall cell lung cancer; 2. the use of BRAF inhibitors dabrafenib and vemurafenib in the treatment of patients with brain metastases due to metastatic melanoma; 3. the use of HER2 agents trastuzumab and lapatinib to treat patients with brain metastases due to metastatic breast cancer; 4. the use of vascular endothelial growth factor agents bevacizumab, sunitinib, and sorafenib in the treatment of patients with solid tumor brain metastases. The full guideline can be found at: https://www.cns.org/guidelines/guidelines-treatmentadults-metastatic-brain-tumors/chapter_9. www.neurosurgery-online.com B rain metastases associated with systemic cancer remain challenging to treat. Current standard treatment modalities, including surgery and radiation, cannot be applied to all patients, and are not uniformly successful when applied. Therefore, novel treatment strategies are necessary.
METHODS
Electronic databases including MEDLINE and Cochrane were searched from September 2008 (end date of prior search) through December 2015 (uniform cutoff established for current guidelines series). Details regarding specific terms used for the literature search, inclusion criteria, and exclusion criteria are available in the full text of the manuscript (https://www.cns.org/guidelines/ guidelines-treatment-adults-metastatic-brain-tumors/chapter_9). Clinical studies included in the creation of guidelines addressing the questions in this manuscript were required to meet criteria as outlined in the full text of this article. Manuscripts selected for review were subclassified based on which question was addressed. Critical analysis of the data determined the class of evidence supported by the paper. The pertinent data and recommendation levels for each paper were entered into an evidence table for each emerging therapy subtopic. The evidence tables were then validated among the writing group prior to determining final evidence class for each manuscript pertinent each question. Each manuscript was evaluated by the writing group for bias, and the summation of different forms of bias is reflected in the classification system. With classified data in hand, recommendations were formulated based on this information with the method of linkage described in Joint Guidelines Review Committee Guideline Development Methodology (https://www.cns.org/guidelines/guideline-procedures-policies/guidelinedevelopment-methodology).
RESULTS
Overall, 74 new studies met eligibility criteria. Recommendations were developed specifically for the treatment of brain metastases. For 4 emerging therapy categories (immune modulators, interstitial modalities, high-intensity focused ultrasound [HIFU] and laser interstitial thermal therapy [LITT]), critical review of available studies over the specified time frame revealed insufficient evidence was available to make a recommendation regarding their use. For the radiation sensitizer category, level 1 recommendations were made against use of temozolomide in the setting of whole brain radiotherapy (WBRT) for patients with ABBREVIATIONS: HIFU, high-intensity focused ultrasound; LITT, laser interstitial thermal therapy; WBRT, whole-brain radiotherapy breast cancer and against the use of chloroquine in the setting of WBRT for patients with brain metastases. Finally, in the category of molecular targeted agents, level 1 recommendation was made against the use of afatinib in patients with breast cancer brain metastases. For other molecular targeted agents such as erlotinib, gefitinib, dabrafenib, vemurafenib, trastuzumab, lapatinib, sunitinib, bevacizumab, and sorafenib, insufficient evidence was available to make a recommendation.
DISCUSSION AND CONCLUSION
Emerging therapies for brain metastases involve a number of treatment categories. Systemic therapies include categories such as molecular targeted agents, immune therapy, and radiation sensitizers. Local strategies include interstitial modalities, LITT, and HIFU. The near future will likely see a continued explosion of data regarding the varied new molecular and immune modulatory agents, and results from trials published after 2015 will be key components in the development of future guidelines. The key to delineating a role for each agent specific to treatment of brain metastases will be well-designed clinical trials.
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